EGFR and prostate carcinoma: MiR-137 also inhibits prostate cancer cell migration and epithelial-mesenchymal transition (EMT) by negatively regulating the epidermal growth factor receptor/extracellular signal-regulated kinase (EGFR/ERK) through LGR4 targeting [38].